Figure 6.

Multimodal imaging of Man(6)-Alb-FL in lung metastasis models. (A) Representative SPECT/CT images (MIP) with [¹¹¹In]In-Man(6)-Alb-FL in tumor-free (TF) and 4T1-bearing mice (TB) on days 21 and 28. The images revealed that [¹¹¹In]In-Man(6)-Alb-FL was able to detect lung metastases (LM, yellow arrowheads) at an earlier time (day 21) when metastatic burden was relatively low. A strong signal was also observed in the lymph node (white arrowhead). (B) Quantification of [¹¹¹In]In-Man(6)-Alb-FL signal in the resected lung, expressed as % ID/g. (C) Ex vivo biodistribution of [¹¹¹In]In-Man(6)-Alb-FL in various organs of 4T1-bearing mice 21 days after tumor injection. (D–H) Simultaneous PET/MRI imaging of [⁶⁴Cu]Cu-Man(6)-Alb-FL and CT imaging were performed in tumor-free (TF) and 4T1-bearing mice (TB) on days 21 and 28. (D) Representative PET/MRI images of [⁶⁴Cu]Cu-Man(6)-Alb-FL. (E) Quantification of [⁶⁴Cu]Cu-Man(6)-Alb-FL signal in the resected lung, expressed as % ID/g. (F) Representative H&E stained images and quantification of metastatic lesion area in lungs from 4T1-bearing mice on days 21 and 28. Scale bar = 50 μm. (G,H) MRI (G) and CT (H) images (coronal, transverse, and sagittal views) are also shown. Representative MRI and CT images show strong signals from lung metastases on day 28, while no significant change was detected at an earlier stage (day 21). n = 5–10 mice/group. Data represent mean ± SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001 using Student’s t test.